BioReference Laboratories, Inc. Announces Strategic Acquisition

BioReference Laboratories, Inc. Announces Strategic Acquisition

California Acquisition Provides West Coast Presence

ELMWOOD PARK, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- BioReference
Laboratories, Inc. (Nasdaq:BRLI) announced today that it completed the
acquisition of a clinical laboratory in northern California. The Company
believes that the California acquisition represents significant strategic
value to its national presence, as well as a significant presence in the
California market.

The Company acquired most of the assets of Hunter Laboratories, located in the
Bay area.The acquisition of Hunter assets provides the Company a West Coast
presence with complex capability as well as Medi-Cal in-network status.The
acquisition from Hunter includes most of its current business and a
sophisticated facility that the Company will use as a base of operations for
its growing western U.S. business.The Company believes that its existing
comprehensive payer relationships will greatly enhance the anticipated
business opportunities of the acquisition.

Marc D. Grodman, MD, CEO, commented: "We believe this acquisition will provide
us with a local West Coast presence that should prove to be a valuable driver
in our continued growth over the next few years.We are a national laboratory
and expect to benefit from a strategic presence in key areas around the
country to support our national capabilities.BioReference participates as a
network provider with most national payers and we anticipate our comprehensive
payer coverage should greatly enhance the existing Hunter business.More
importantly, we believe that having a local base for operations can provide
significant operational and logistical synergies as we continue to grow our
national footprint throughout the western United States."

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases.BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements".
Forward-looking statements may be identified by words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or
words of similar meaning and include, but are not limited to, statements about
the expected future business and financial performance of Bio-Reference
Laboratories,Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on forward-looking statements, which speak only as of the
date they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and uncertainties
that could cause actual results and outcomes to be materially different.Risks
and uncertainties that may affect the future results of the company include,
but are not limited to, adverse results from pending or future government
investigations, lawsuits or private actions, the competitive environment,
changes in government regulations, changing relationships with customers,
payers, suppliers and strategic partners, the ability to expand our West Coast
business and other and other risks and uncertainties detailed from time to
time in our filings with the Securities and Exchange Commission. We undertake
no obligation to publicly update or review any forward-looking information,
whether as a result of new information, future developments or otherwise.


CONTACT: Tara Mackay
         Investor Relations Coordinator
         (201) 791-2600
         (201) 791-1941 (fax)
Press spacebar to pause and continue. Press esc to stop.